Cite
Gadelha M, Bex M, Colao A, et al. Evaluation of the Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Inadequately Controlled With First-Generation Somatostatin Analogs. Front Endocrinol (Lausanne). 2020;10:931doi: 10.3389/fendo.2019.00931.
Gadelha, M., Bex, M., Colao, A., Pedroza García, E. M., Poiana, C., Jimenez-Sanchez, M., Yener, S., Mukherjee, R., Bartalotta, A., Maamari, R., & Raverot, G. (2019). Evaluation of the Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Inadequately Controlled With First-Generation Somatostatin Analogs. Frontiers in endocrinology, 10931. https://doi.org/10.3389/fendo.2019.00931
Gadelha, Mônica, et al. "Evaluation of the Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Inadequately Controlled With First-Generation Somatostatin Analogs." Frontiers in endocrinology vol. 10 (2019): 931. doi: https://doi.org/10.3389/fendo.2019.00931
Gadelha M, Bex M, Colao A, Pedroza García EM, Poiana C, Jimenez-Sanchez M, Yener S, Mukherjee R, Bartalotta A, Maamari R, Raverot G. Evaluation of the Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Inadequately Controlled With First-Generation Somatostatin Analogs. Front Endocrinol (Lausanne). 2020 Feb 03;10:931. doi: 10.3389/fendo.2019.00931. eCollection 2019. PMID: 32117045; PMCID: PMC7008501.
Copy
Download .nbib